PARP1 and acute myeloid leukemia: Since there are several FDA-approved PARP inhibitors available as well as ongoing clinical trials involving treating AML/MDS with PARP inhibitors [65,66], clinical trials involving treating MECOM-R AML patients with PARP inhibitors may be available soon.